Prognostic and clinicopathological role of pretreatment fibrinogen-to-albumin ratio (FAR) in patients with gastric cancer: a meta-analysis

胃癌患者治疗前纤维蛋白原与白蛋白比值(FAR)的预后和临床病理作用:一项荟萃分析

阅读:1

Abstract

BACKGROUND: Fibrinogen-to-albumin ratio (FAR) has been previously suggested for its significance in forecasting gastric cancer (GC) prognosis, however, the results remained conflicting. The present work focused on clarifying FAR's accurate effect on forecasting GC prognosis via meta-analysis. METHODS: This study thoroughly retrieved PubMed, Web of Science, Embase, Cochrane Library, and CNKI until January 4, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to forecast FAR's role in forecasting GC overall survival (OS) and disease-free survival (DFS). RESULTS: We retrieved 12 studies recruiting 5665 cases in the present work. From the pooled findings, high FAR exhibited significant relation to unfavorable OS (HR = 1.68, 95%CI = 1.38-2.04, p < 0.001) of patients with GC. But FAR was not apparently linked with DFS of GC (HR = 1.24, 95%CI = 0.69-2.22, p = 0.468). According to our combined findings, elevated FAR exhibited significant connection to age ≥ 60 years (OR = 2.13, 95%CI = 1.72-2.65, p < 0.001), tumor size ≥ 5 cm (OR = 1.91, 95%CI = 1.13-3.24, p = 0.016), and TNM stage of III-IV (OR = 2.5, 95%CI = 2.08-3.23, p < 0.001). Nonetheless, FAR remained insignificantly linked with gender (OR = 1.16, 95%CI = 0.94-1.43, p = 0.162), invasion depth (OR = 2.01, 95%CI = 1.00-4.04, p = 0.050), N stage (OR = 1.30, 95%CI = 0.63-2.67, p = 0.482), tumor differentiation (OR = 1.22, 95%CI = 0.93-1.62, p = 0.153), and vascular invasion (OR = 1.11, 95%CI = 0.68-1.81, p = 0.687) of GC patients. CONCLUSION: In the present study, increased FAR dramatically predicted the dismal OS of GC. Moreover, high FAR showed obvious relation to older age, larger tumor size, and advanced stage of GC cases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。